Estrone

Estrone (E1) is a steroid hormone classified as one of the three main estrogens, primarily produced in the ovaries, adrenal glands, and peripheral tissues, particularly in postmenopausal women. Researchers primarily study estrone for its role in breast cancer development and its interactions with other hormones. Key findings indicate that intratumoral enzymes, such as 17beta-hydroxysteroid dehydrogenase type 1, can convert estrone to the more potent estradiol, suggesting a significant role for estrone in hormone-dependent breast carcinoma. Additionally, studies suggest that estrone may act as a partial antagonist to estradiol in breast tissue, complicating the relationship between these hormones in cancer biology. Current research continues to explore the implications of estrone in breast cancer prognosis and treatment, highlighting its potential as a target for novel endocrine therapies.

Estrone (E1), also known as oestrone, is an endogenous estrogen and one of the three main estrogens produced by the human body, alongside estradiol (E2) and estriol (E3). It is primarily produced in the ovaries, adipose tissue, and adrenal glands. Estrone belongs to the chemical class of steroid hormones and is a weak estrogen compared to estradiol. In postmenopausal women, estrone becomes the predominant form of estrogen due to decreased ovarian production of estradiol. Researchers have observed that estrone plays a significant role in the pathogenesis of hormone-dependent breast carcinoma, particularly in postmenopausal women. It is involved in the intratumoral metabolism of estrogens, where enzymes such as 17beta-hydroxysteroid dehydrogenase (17beta-HSD) interconvert estrone and estradiol, influencing the local estrogenic environment. Estrone acts primarily through estrogen receptors, particularly the alpha subtype, and can modulate estrogenic actions in tissues. It serves as both a precursor and a metabolite of estradiol, with estrone sulfate acting as a large reservoir in the body. Pharmacokinetically, estrone is subject to significant first-pass metabolism when administered orally, resulting in variations in serum concentrations. It is interconvertible with estradiol, dependent on local tissue concentrations. Clinically, estrone is not commonly used in hormone replacement therapy due to its weaker estrogenic activity compared to estradiol. Its regulatory standing varies by country, with specific legal requirements for its use and prescription.

Estrone acts primarily on estrogen receptors, particularly the ER-alpha subtype, leading to the modulation of gene expression and cellular responses. This interaction influences cell proliferation and differentiation, especially in estrogen-sensitive tissues such as breast tissue.

Estrone (E1) primarily acts as an estrogen receptor agonist, particularly binding to estrogen receptor alpha (ERα) and beta (ERβ), which activates downstream signaling pathways such as the MAPK/ERK pathway and PI3K/Akt pathway, promoting cell proliferation and survival. E1 can also function as a partial antagonist to estradiol (E2) in certain contexts, potentially disrupting the normal estrogenic signaling in breast tissue. The exact mechanisms of E1's dual role and its interactions with other signaling pathways remain incompletely understood.

Current evidence is limited regarding the specific roles and interactions of estrone (E1) in various breast cancer subtypes, particularly concerning its dual role as both a weak estrogen and a potential partial antagonist to estradiol (E2). Further research is needed to clarify the mechanisms by which E1 influences breast cancer progression, especially in hormone-independent cancer cells, and to explore the therapeutic implications of targeting intratumoral enzymes like 17beta-HSD and estrogen sulfotransferase in diverse patient populations. Additionally, larger randomized controlled trials are necessary to assess the long-term effects of E1 in hormone replacement therapy and its impact on breast tissue dynamics in postmenopausal women.